Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK taps RNA-targeting start-up for cancer deal
by Rowan Walrath
December 8, 2024
| A version of this story appeared in
Volume 102, Issue 38
GSK will pay 4-year-old start-up Rgenta Therapeutics up to $46 million in up-front cash and preoption milestone payments—with the potential for up to $500 million in additional milestone payments—to develop small-molecule splice modulators for cancers and other diseases. Rgenta’s molecules are designed to stop RNA from encoding proteins that cause diseases. The firm launched in 2020 with $20 million in seed funding and raised $52 million in a series A round in 2022.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X